[Skip to content]

European Parkinson's Disease Association
Search our Site


Νόσοσ του πάρκινσον – διαφορετικέσ σκοπιέσ

  • Balami J, Robertson D. Parkinson’s disease and sexuality. Br J Hosp Med (Lond). 2007; 68: 644-7. Review

  • Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson’s disease. CNS Spectr. 2006; 11: 541-54. Review

  • Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006; 5: 235-45.

  • Chou KL, Evatt M, Hinson V, Kompoliti K. Sialorrhea in Parkinson’s disease: a review. Mov Disord. 2007; 22: 2306-13. Review

  • Clarke CE. Parkinson’s disease. BMJ. 2007; 335: 441-5. Review

  • Comella CL. Sleep disorders in Parkinson’s disease: an overview. Mov Disord. 2007; 22 Suppl 17: S367-73. Review

  • Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson’s disease. Age Ageing. 2006; 35: 220-8. Review

  • Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson’s disease. Drugs Aging. 2006; 23: 693-721. Review

  • Dubow JS. Autonomic dysfunction in Parkinson’s disease. Dis Mon. 2007

  • Freedom T. Sleep and Parkinson’s disease. Dis Mon. 2007; 53: 275-90. Review

  • Goldmann Gross R, Siderowf A, Hurtig HI. Cognitive impairment in Parkinson’s disease and dementia with lewy bodies: a spectrum of disease. Neurosignals. 2008; 16: 24-34. Review

  • Grujic Z. Cognitive disturbances in Parkinson’s disease. Dis Mon. 2007; 53: 302-8. Review

  • Jankovic J. Parkinson’s disease and movement disorders: moving forward. Lancet Neurol. 2008; 7: 9-11. Review

  • Kashihara K. Weight loss in Parkinson’s disease. J Neurol. 2006; 253 Suppl 7: VII38-41. Review

  • Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using non-motor symptoms questionnaire in 545 patients. Mov Disord. 2007; 22: 1623-9.

  • Munno D, Caporale S, Zullo G, Sterpone S, Malfatto A, Zeme S, Pagni CA. Neuropsychologic assessment of patients with advanced Parkinson disease submitted to extradural motor cortex stimulation. Cogn Behav Neurol. 2007; 20: 1-6.

  • Papatsoris AG, Deliveliotis C, Singer C, Papapetropoulos S. Erectile dysfunction in Parkinson’s disease. Urology. 2006; 67: 447-51. Review

  • Richard IH. Anxiety disorders in Parkinson’s disease. Adv Neurol. 2005; 96: 42-55. Review

  • Rolan T. Sleep and Parkinson’s disease. Mo Med. 2006; 103: 529-32. Review

  • Rubin SM. Parkinson’s disease in women. Dis Mon. 2007; 53: 206-13. Review

  • Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP. Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord. 2007; 22: 938-45

  • Stewart L. Using nursing skills to relieve the symptoms of Parkinson’s disease. Interview by Anne Manchester. Nurs N Z. 2008; 14: 16-7

  • Tolosa E, Compta Y. Dystonia in Parkinson’s disease. J Neurol. 2006; 253 Suppl 7:VII7-13. Review

  • Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci. 2008; 266: 216-28

  • Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007; 22: 220-5

  • Zesiewicz TA, Sullivan KL, Hauser RA. Nonmotor symptoms of Parkinson’s disease. Expert Rev Neurother. 2006; 6: 1811-22. Review

  • Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2007; 13: 323-32. Review

  • World Health Organisation. Neurological Disorders: public health challenges - Parkinson’s Disease, 2006; 3.8: 140–150



  • Antonini A. Continuous dopaminergic stimulation--from theory to clinical practice. Parkinsonism Relat Disord. 2007 Suppl:S24-8. Review

  • Blahak C, Wöhrle JC, Capelle HH, Bäzner H, Grips E, Weigel R, Hennerici MG, Krauss JK. Tremor reduction by subthalamic nucleus stimulation and medication in advanced Parkinson’s disease. J Neurol. 2007; 254: 169-78

  • Coelho M, Ferreira J, Rosa M, Sampaio C. Treatment options for non-motor symptoms in late-stage Parkinson’s disease. Expert Opin Pharmacother. 2008; 9):523-35. Review

  • Diamond A, Jankovic J. Treatment of advanced Parkinson’s disease. Expert Rev Neurother. 2006; 6: 1181-97. Review

  • Fargel M, Grobe B, Oesterle E, Hastedt C, Rupp M. Treatment of Parkinson’s disease: a survey of patients and neurologists. Clin Drug Investig. 2007; 27: 207-18

  • Giroux ML. Parkinson disease: managing a complex, progressive disease at all stages. Cleve Clin J Med. 2007; 74: 313-4, 317-8, 320-2. Review

  • Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson’s disease: a review. Expert Opin Pharmacother. 2007; 8: 2799-809. Review

  • Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C; Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson’s disease. Eur J Neurol. 2006; 13: 1186-202. Review

  • Lew M. Overview of Parkinson’s disease. Pharmacotherapy. 2007; 27 (12 Pt 2): 155S-160S. Review

  • Melamed E, Ziv I, Djaldetti R. Management of motor complications in advanced Parkinson’s disease. Mov Disord. 2007; 22 Suppl 17: S379-84. Review

  • Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005; 64: 216-23

  • Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007; 13 Suppl:S13-7. Review

  • Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s disease. Expert Rev Neurother. 2006; 6: 1403-11. Review

  • Pahwa R, Koller WC, Trosch RM, Sherry JH; APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007; 258: 137-43

  • Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007; 6: 513-20

  • The Entacapone to Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov Disord. 2007; 22: 14-9

  • Tse W. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon. J Am Med Dir Assoc. 2006; 7 Suppl 2: 12-7. Review

  • Westin J, Nyholm D, Groth T, Dougherty MS, Yerramsetty PK, Palhagen SE. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2006; 12: 509-13

  • Wolters ECh. Deep brain stimulation and continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007; 13: S18-23. Review

  • Yu H, Neimat JS. The treatment of movement disorders by deep brain stimulation. Neurotherapeutics. 2008; 5: 26-36. Review


  Νόσοσ του Πάρκινσον – ΠΑΡενέργειεσ

  • Bhidayasiri R, Truong DD. Motor complications in Parkinson’s disease: clinical manifestations and management. J Neurol Sci. 2008; 266: 204-15. Review

  • Bonvin C, Horvath J, Christe B, Landis T, Burkhard PR. Compulsive singing: another aspect of punding in Parkinson’s disease. Ann Neurol. 2007; 62: 525-8

  • Ferreri F, Agbokou C, Gauthier S. Recognition and management of neuropsychiatric complications in Parkinson’s disease. CMAJ. 2006; 175: 1545-52. Review

  • Hauser RA. Long-term care of Parkinson’s disease. Strategies for managing “wearing off” symptom re-emergence and dyskinesias. Geriatrics. 2006; 61: 14-20. Review

  • Kessler A, Rezak M. Complications of dopaminergic therapy. Dis Mon. 2007; 53: 223-6. Review

  • Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins. Expert Rev Neurother. 2007; 7: 1731-50. Review

  • O’Sullivan SS, Evans AH, Lees AJ. Punding in Parkinson’s disease. Pract Neurol. 2007; 7: 397-9.

  • Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive deficits and psychosis in Parkinson’s disease: a review of pathophysiology and therapeutic options. CNS Drugs. 2006; 20: 477-505. Review

  • Wolters ECh. PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl. 2006; 71: 31-7. Review

  • Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson’s disease: epidemiology, etiology, and treatment. Curr Neurol Neurosci Rep. 2007; 7: 302-10. Review



  • Boeve BF. Parkinson-related dementias. Neurol Clin. 2007; 25: 761-81. Review

  • McKeith I. Dementia with Lewy bodies and Parkinson’s disease with dementia: where two worlds collide. Pract Neurol. 2007; 7: 374-82. Review

  • Metzler-Baddeley C. A review of cognitive impairments in dementia with Lewy bodies relative to Alzheimer’s disease and Parkinson’s disease with dementia. Cortex. 2007; 43: 583-600. Review

  • Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008; 23: 183-9; quiz 313. Review

  • Richard IH. Depression and apathy in Parkinson’s disease. Curr Neurol Neurosci Rep. 2007; 7: 295-301